Breakthrough new NHS drug can delay spread of breast cancer

Breakthrough new NHS drug can delay spread of breast cancer Breast cancer sufferers will be granted extra months of life thanks to a new drug that has been approved for NHS use.

Enhertu, or trastuzumab deruxtecan, will be rolled out to 600 women a year in England. Trials have shown that that drug improves the survival of recipients by halting the spread of tumours.

It gives patients an extra 22 months of life, on average, before the cancer progresses. The Independent

See also:

• Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies NICE